Evidence map›Paper›PMID 32342015›Full record

ArticleBMJ paediatrics open2020

Paediatric drugs trials in China.

Guo-Xiang Hao, Xiao-Xiao Yuan, Wei Guo, Xi-Yu Quan, Xue-Jie Qi, Tian-You Wang, Wei Zhao

Abstract read
In one paragraph

Article in BMJ paediatrics open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Guo-Xiang HaoDepartment of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.
Xiao-Xiao YuanDepartment of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.
Wei GuoDepartment of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.
Xi-Yu QuanDepartment of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.
Xue-Jie QiDepartment of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.
Tian-You WangBeijing Key Laboratory of Paediatric Hematology Oncology, National Key Discipline of Paediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China.
Wei ZhaoDepartment of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.ORCID 0000-0002-1830-338X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveClinical trials of children's drugs are of great significance to rational drug use in children. However, paediatric drugs trials in China are facing complex challenges. At present, the investigation data on registration status of paediatric drug trials in China are still relatively lacking, and relevant research is urgently needed.

methodsThe advanced retrieval function is used to retrieve clinical trials data in the Clinical Trial.gov and Chinese Clinical Trial Registry databases in 22 April 2019. Fifteen key items were analysed to describe trial characteristics, including: registration number, study start date (year), mode of funding, type of disease, medicine type, research stage, research design, sample size, number of experimental groups, placebo group, blind method, implementation centre, child specific, newborn specific and participant age.

resultsA total of 1388 clinical trials of paediatric drugs conducted in China were registered. The number of paediatric drug trials grew steadily over time, from less than 20 per year before 2005 to more than 100 per year after 2012. Most clinical trials were postmarketing (n=800, 57.6%), single-centre (n=1045, 75.3%), intervention studies (n=1161, 83.6%) without blinded methods (1169, 84.2%) and funded by non-profit organisations (n=838, 60.4%). The number of clinical trials for antineoplastic agents (n=254, 18.3%), anti-infectives (n=156, 11.2%) and vaccines (n=154, 11.1%) is the largest.

conclusionPaediatric drug trials in China made a significant progress in recent years. Innovative method and trial design optimisation should be encouraged to accelerate paediatric clinical research. Pharmaceutical companies need to be further stimulated to carry out more high-quality paediatric clinical trials with support of paediatric drug legislation.

Indexed as

evidence based medicinepaediatric practice

Identifiers

PMID32342015
PMCPMC7173953

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.